TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) dropped 0% on Wednesday . The stock traded as low as $0.59 and last traded at $0.69. Approximately 808,246 shares traded hands during mid-day trading, an increase of 618% from the average daily volume of 112,624 shares. The stock had previously closed at $0.69.

TEAR has been the subject of several analyst reports. Zacks Investment Research downgraded TearLab Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of TearLab Corporation in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $4.90.

The company has a debt-to-equity ratio of -2.03, a current ratio of 2.60 and a quick ratio of 2.14.

TearLab Corporation (NASDAQ:TEAR) (TSE:TLB) last issued its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $6.86 million. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.08) EPS. analysts anticipate that TearLab Corporation will post -2.64 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “TearLab Corporation (TEAR) Shares Down 0%” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/08/tearlab-corporation-tear-shares-down-0.html.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Receive News & Stock Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related stocks with our FREE daily email newsletter.